Statins and bone: Myth or reality?

TY - JOUR

T1 - Statins and bone: Myth or reality?

AU - Edwards, C J

AU - Russell, R G G

AU - Spector, T D

PY - 2001

Y1 - 2001

N2 - In the space of a few weeks, four articles appeared in the The Lancet and JAMA suggesting that using 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors (statins) is associated with increased bone mineral density (BMD) [1] and a reduced fracture risk [2-4]. The stimulus for these case-control studies came from reports that the statins have unexpected effects on bone, increasing bone formation in rodents [5]. These observations offered a new insight into the potential importance of the cholesterol synthesis pathway in bone turnover and future therapeutic opportunities.

AB - In the space of a few weeks, four articles appeared in the The Lancet and JAMA suggesting that using 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors (statins) is associated with increased bone mineral density (BMD) [1] and a reduced fracture risk [2-4]. The stimulus for these case-control studies came from reports that the statins have unexpected effects on bone, increasing bone formation in rodents [5]. These observations offered a new insight into the potential importance of the cholesterol synthesis pathway in bone turnover and future therapeutic opportunities.

M3 - Literature review

VL - 69

SP - 63

EP - 66

JO - Calcified Tissue International

JF - Calcified Tissue International

IS - 2

ER -